Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-2280 vaginal tablet dose-escalation study in cervical squamous intraepithelial lesions
ACTRN12622001065785Phase 2Not yet recruiting
- Sponsor
- Antiva Biosciences
- Start
- Aug 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of ABI-2280 in cervical intraepithelial neoplasia (CIN) (3 cohorts), sponsored by Antiva Biosciences. Primary endpoint: Safety and tolerability. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
ABI-2280
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on ACTRN12622001065785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001065785.